Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations (Heat on Beat study)

Background: In the FLAURA trial, superiority of osimertinib over the standard of care (SOC) was not demonstrated in Asian patients; SOC seemed favorable among Japanese patients (hazard ratio 1.39, 95% confidence interval 0.82–2.33). Three reasons are suggested: since rechallenge with epidermal growt...

Full description

Bibliographic Details
Main Authors: Kei Morikawa, Hisashi Tanaka, Hidetoshi Itani, Saori Takata, Satoshi Watanabe, Kazuma Kishi, Kenzo Soejima, Kyoichi Kaira, Hiroshi Kagamu, Kenichi Yoshimura, Noriyuki Matsutani, Nobuhiko Seki
Format: Article
Language:English
Published: SAGE Publishing 2020-10-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835920967254

Similar Items